


Forward-looking Statements

This presentation contains forward-looking statements. These statements may be identified by words such as "expect," "should," "could," "shall," and similar expressions. Wolters Kluwer cautions that such forward-looking statements are qualified by certain risks and uncertainties that could cause actual results and events to differ materially from what is contemplated by the forward-looking statements. Factors which could cause actual results to differ from these forward-looking statements may include, without limitation, general economic conditions; conditions in the markets in which Wolters Kluwer is engaged; behavior of customers, suppliers, and competitors; technological developments; the implementation and execution of new ICT systems or outsourcing; and legal, tax, and regulatory rules affecting Wolters Kluwer's businesses, as well as risks related to mergers, acquisitions, and divestments. In addition, financial risks such as currency movements, interest rate fluctuations, liquidity, and credit risks could influence future results. The foregoing list of factors should not be construed as exhaustive. Wolters Kluwer disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Wolters Kluwer

Morgan Stanley European TMT Conference

November 14, 2007 - Barcelona



Wolters Kluwer

- Global information services and publishing company
- Leading positions in core markets: health, tax, accounting, corporate services, financial services, law, and regulation
- Euronext listed (AEX index)
- Market Capitalization €6.6 billion (November 12, 2007)
- Revenues of €3.4 billion*
- Approximately 18,450 employees
- In more than 30 countries across 5 continents

The Professional's First Choice:

Provide the information, tools, and solutions to help professionals make their critical decisions and improve their productivity


*restated for continuing operations


Wolters Kluwer

Morgan Stanley European TMT Conference

November 14, 2007 - Barcelona


	Revenues 2006 (mln)	EBITA margin	Key Vertical Brands	Core Markets
Health	€823	15%	Lippincott Williams & Wilkins Ovid Adis Adis Source Healthcare Analytics Medi-Span/Facts & Comparisons	Clinical solutions Medical research Pharma solutions Professional & education
CFS	€534	22%	CT UCC Direct Services CT TyMetrix / CT Summation WK Financial Services Bankers Systems PCi / VMP	Business Entity Compliance Governance Litigation management Practice management Banking and insurance Securities and mortgage
TAL	€826	18%	CCH ProSystem Aspen ATX/Kleinrock	Tax research Tax compliance Specialty legal Productivity tools and softw
LTRE	€1,194	18%	Kluwer Lamy La Ley Croner CCH At3s TeleRoute	Broad legal coverage HR professionals Tax & accounting profession Health, safety and environment Transport services















Significant Progress in Executing Strategy ■ International expansion -- particularly, India, China and Latin **America** ■ Globalization of successful product lines - e.g., ProSystem.fx, cale and ■ Shared/common IT platform investments - e.g, Atlas, Ceres ■ Adaptations and translations of core products - e.g., Health Spanish language program, Italian legal suite, Securities **Compliance Solutions** ■ Customer Intimacy are driving product development initiatives - e.g., Ovid SP ■ Six sigma initiatives have multiplied with the growing number of trained green and black belts ■ Cross divisional sourcing initiatives continue to deliver savings - e.g., NASS, LTRE Wolters Kluwer Morgan Stanley European TMT Conference November 14, 2007 - Barcelona 11









Accelerated Growth in Q3; Reiterated FY Guidance Q3 Highlights: Key Financial Results*

- Revenue of €799 million (2% Growth; 6% in constant currencies)
- Organic revenue growth of 4%
- Ordinary EBITA of €153 million (18% Growth; 24% in constant currencies)
- Ordinary EBITA margin improved to 19% (2006: 16%)
- Structural cost savings of €41 million (24% improvement over prior year)
- Free cash flow of €76 million (materially in line with prior year)
- Ordinary diluted earnings per share increased 32% (40% in constant currencies)
- * From continuing operations

Wolters Kluwer

Morgan Stanley European TMT Conference

November 14, 2007 - Barcelona

Accelerated Growth YTD; Reiterated FY Guidance

Year-to-Date September: Key Financial Results*

- Revenue of €2,476 million (2% Growth; 6% in constant currencies)
- Organic revenue growth of 3% (on track to meet full-year guidance)
- Ordinary EBITA of €457 million (20% Growth; 26% in constant currencies)
- Ordinary EBITA margin improved to 18% (2006: 16%)
- Structural cost savings of €117 million (2006: 29% improvement over prior year)
- Free cash flow of €194 million (8% increase over prior year excluding tax refund)
- Ordinary diluted earnings per share increased by 23% (32% in constant currencies)
- * From continuing operations

Wolters Kluwer

Morgan Stanley European TMT Conference

November 14, 2007 - Barcelona

On Track to Achieve Full-Year KPIs

Key Operational Measures	Actual YTD September 2006	Actual YTD September 2007	Target Full-Year 2007
Organic Revenue Growth	2%	3%	4%
Ordinary EBITA Margin	16%	18%	19-20%
Cash Conversion	85%	77%	95-105%
Key Financial Measures			
Free Cash Flow	€232 mln	€194 mln	± €425 mln
ROIC % ¹	n/a	n/a	≥ WACC ²
Ordinary Diluted EPS ³	€0.72	€0.96	€1.45-€1.50

¹ After tax ² Currently WACC is 8% after tax ³ At constant currencies EUR/USD 1.26

Wolters Kluwer

November 14, 2007 - Barcelona

Additional Share Buy-back Program Announced

- Original Share Buy-back Program €475 Million Program
 - Announced March 2007
 - Share purchased through November 2, 2007: 21.1 million
 - Total consideration paid through November 2, 2007: €459 million
 - Program 97% complete
 - Anticipate completion of program by year-end 2007
- Additional Share Buy-back Program €175 Million Program
 - Announced November 2007
 - Above and beyond the current progressing $\ensuremath{\not\in} 475$ million program
 - Estimated additional shares to be repurchased: approximately 8.0 million 1
 - Program begins after the completion of the existing program
 - Program expected to conclude in April 2008 or earlier if:
 - ⇒ Aggregate value of shares acquired exceeds €175 million
 - ⇒ 10% of ordinary shares have been repurchased (including shares already held)


¹ Based on closing share price of November 6, 2007





Morgan Stanley European TMT Conference


November 14, 2007 - Barcelona














Key Operational Measures	2003	2004	2005	20064	2007 ^{1,4}	Beyond 2007 ^{1,4}
Organic Revenue Growth	-2%	1%	2%	3%	4%	4-5%
Ordinary EBITA Margin	18%	16%	16%	17%	19-20%	Continuous improvemer
Cash Conversion	109%	126%	106%	100%	95-105%	95-105%
Key Financial Measures						
Free Cash Flow	€393 million	€456 million	€351 million	€399 million	± €425 million	> €425 million
ROIC % ²	7%	7%	7%	7%	≥ WACC ³	> WACC ³
Ordinary Diluted EPS	€1.18	€1.02	€1.06	€1.09 ¹	€1.45-€1.50	Double-digi



